Iceland is the fourth country in the EU, after Norway, Denmark and Italy, to suspend vaccinations with AstraZeneca following reports of serious side effects. This was announced today, March 11, by the country’s Health Directorate.
“AstraZeneca vaccination is temporarily suspended in Iceland,” the report said.
Prior to this, Denmark and Norway suspended vaccination with AstraZeneca, as information about thrombus formation in vaccinated patients appeared. The European Medicines Agency (EMA) has begun a study on the AstraZeneca vaccine, but “it cannot be concluded at this time whether there is a link between the vaccine and blood clots.” Later, a similar decision was reported by the Italian authorities.
Against this backdrop, the EMA has recommended that community countries continue to use the AstraZeneca vaccine:
“The EMA’s position is that the benefits of the vaccine still outweigh the risks, and the vaccine can continue to be administered while investigations of thromboembolic events continue. … The number of thromboembolic events in vaccinated people does not exceed their number in the general population. As of March 10, there were 30 cases of thromboembolism reported in the EU among nearly 5 million people vaccinated with the AstraZeneca vaccine. ”